The utility of prostate‐specific antigen velocity thresholds in clinical practice: a population‐based analysis
OBJECTIVE To investigate the ability of prostate‐specific antigen velocity (PSAV) to predict prostate cancer, and assess the test characteristics of several PSAV thresholds for identifying prostate cancer and high‐grade cancers. PATIENTS AND METHODS From a population‐based database of PSA results, m...
Gespeichert in:
| Veröffentlicht in: | BJU international 2008-06, Vol.101 (12), p.1507-1512 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1512 |
|---|---|
| container_issue | 12 |
| container_start_page | 1507 |
| container_title | BJU international |
| container_volume | 101 |
| creator | Connolly, David Black, Amanda Murray, Liam J. Nambirajan, Thiagarajan Keane, Patrick F. Gavin, Anna |
| description | OBJECTIVE
To investigate the ability of prostate‐specific antigen velocity (PSAV) to predict prostate cancer, and assess the test characteristics of several PSAV thresholds for identifying prostate cancer and high‐grade cancers.
PATIENTS AND METHODS
From a population‐based database of PSA results, men with an initial PSA level of |
| doi_str_mv | 10.1111/j.1464-410X.2008.07470.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70767556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70767556</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4470-d9f25d81e389427d8cba038ef82826afec16fa6fb909c4f22fc77ff721e19e4f3</originalsourceid><addsrcrecordid>eNqNkEFPHCEUgEmjqbr2LzRc6m2nwLDAmHjQTdUaEy-a9EZY5uGyYWemA6PurT-hv9FfItPd2ms5wAt87z3ehxCmpKB5fV0VlAs-5ZT8KBghqiCSS1K8fECH7w97f2NSiQN0FOOKkHwhZh_RAVUlp4LJQ9TfLwEPyQefNrh1uOvbmEyC11-_YwfWO2-xaZJ_hAY_QWjtyKVlD3HZhjpi32AbfOOtCTnX2OQtnGKDu7Ybgkm-bXKlhYlQ5zImbKKPx2jfmRDh0-6coIfLb_fz6-nt3dX3-fnt1PI8zLSuHJvVikKpKs5krezCkFKBU0wxYRxYKpwRblGRynLHmLNSOicZBVoBd-UEnWzr5pl-DhCTXvtoIQTTQDtELYkUcjYTGVRb0ObhYw9Od71fm36jKdGjb73So0o9atWjb_3Ht37JqZ93PYbFGup_iTvBGfiyA0zMjlxvGuvjO8dIKcsy7xN0tuWefYDNf39AX9w8jFH5BspSoKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70767556</pqid></control><display><type>article</type><title>The utility of prostate‐specific antigen velocity thresholds in clinical practice: a population‐based analysis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Connolly, David ; Black, Amanda ; Murray, Liam J. ; Nambirajan, Thiagarajan ; Keane, Patrick F. ; Gavin, Anna</creator><creatorcontrib>Connolly, David ; Black, Amanda ; Murray, Liam J. ; Nambirajan, Thiagarajan ; Keane, Patrick F. ; Gavin, Anna</creatorcontrib><description>OBJECTIVE
To investigate the ability of prostate‐specific antigen velocity (PSAV) to predict prostate cancer, and assess the test characteristics of several PSAV thresholds for identifying prostate cancer and high‐grade cancers.
PATIENTS AND METHODS
From a population‐based database of PSA results, men with an initial PSA level of <10.0 ng/mL, taken between I January 1994 and 31 December 2003, were identified. Those with three or more PSA tests before diagnosis, taken over ≥18 months, were included. Men were followed for a diagnosis of prostate cancer or histologically confirmed benign disease until 31 December 2003.
RESULTS
In all, 24 709 men were included, with 716 (2.9%) diagnosed with prostate cancer and 1488 (6.0%) with benign histology. The mean (10.38 vs 0.43 ng/mL/year) and median (1.47 vs 0.03 ng/mL/year) PSAV were considerably higher in men with prostate cancer than in those with no cancer (P < 0.001). There was no PSAV threshold that could reliably identify prostate cancer or high‐grade cancers without requiring many men to proceed to prostate biopsy.
CONCLUSION
In this population, PSAV had additional value over one PSA value in identifying men with prostate cancer. Many men with prostate cancer might have a ‘normal’ (<0.75 ng/mL/year) PSAV. As with total PSA level, there was no PSAV threshold that could reliably predict prostate cancer, but rather a continuum of risk of cancer associated with PSAV level.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2008.07470.x</identifier><identifier>PMID: 18341627</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Biological and medical sciences ; cancer ; Cohort Studies ; diagnosis ; Gynecology. Andrology. Obstetrics ; Humans ; initial PSA ; Ireland ; Male ; Male genital diseases ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; population ; prostate ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - pathology ; Registries ; Reproducibility of Results ; Risk Factors ; Sensitivity and Specificity ; Statistics, Nonparametric ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland ; velocity</subject><ispartof>BJU international, 2008-06, Vol.101 (12), p.1507-1512</ispartof><rights>2008 THE AUTHORS. JOURNAL COMPILATION © 2008 BJU INTERNATIONAL</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4470-d9f25d81e389427d8cba038ef82826afec16fa6fb909c4f22fc77ff721e19e4f3</citedby><cites>FETCH-LOGICAL-c4470-d9f25d81e389427d8cba038ef82826afec16fa6fb909c4f22fc77ff721e19e4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1464-410X.2008.07470.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1464-410X.2008.07470.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20373320$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18341627$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Connolly, David</creatorcontrib><creatorcontrib>Black, Amanda</creatorcontrib><creatorcontrib>Murray, Liam J.</creatorcontrib><creatorcontrib>Nambirajan, Thiagarajan</creatorcontrib><creatorcontrib>Keane, Patrick F.</creatorcontrib><creatorcontrib>Gavin, Anna</creatorcontrib><title>The utility of prostate‐specific antigen velocity thresholds in clinical practice: a population‐based analysis</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>OBJECTIVE
To investigate the ability of prostate‐specific antigen velocity (PSAV) to predict prostate cancer, and assess the test characteristics of several PSAV thresholds for identifying prostate cancer and high‐grade cancers.
PATIENTS AND METHODS
From a population‐based database of PSA results, men with an initial PSA level of <10.0 ng/mL, taken between I January 1994 and 31 December 2003, were identified. Those with three or more PSA tests before diagnosis, taken over ≥18 months, were included. Men were followed for a diagnosis of prostate cancer or histologically confirmed benign disease until 31 December 2003.
RESULTS
In all, 24 709 men were included, with 716 (2.9%) diagnosed with prostate cancer and 1488 (6.0%) with benign histology. The mean (10.38 vs 0.43 ng/mL/year) and median (1.47 vs 0.03 ng/mL/year) PSAV were considerably higher in men with prostate cancer than in those with no cancer (P < 0.001). There was no PSAV threshold that could reliably identify prostate cancer or high‐grade cancers without requiring many men to proceed to prostate biopsy.
CONCLUSION
In this population, PSAV had additional value over one PSA value in identifying men with prostate cancer. Many men with prostate cancer might have a ‘normal’ (<0.75 ng/mL/year) PSAV. As with total PSA level, there was no PSAV threshold that could reliably predict prostate cancer, but rather a continuum of risk of cancer associated with PSAV level.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>cancer</subject><subject>Cohort Studies</subject><subject>diagnosis</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>initial PSA</subject><subject>Ireland</subject><subject>Male</subject><subject>Male genital diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>population</subject><subject>prostate</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Registries</subject><subject>Reproducibility of Results</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Statistics, Nonparametric</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><subject>velocity</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEFPHCEUgEmjqbr2LzRc6m2nwLDAmHjQTdUaEy-a9EZY5uGyYWemA6PurT-hv9FfItPd2ms5wAt87z3ehxCmpKB5fV0VlAs-5ZT8KBghqiCSS1K8fECH7w97f2NSiQN0FOOKkHwhZh_RAVUlp4LJQ9TfLwEPyQefNrh1uOvbmEyC11-_YwfWO2-xaZJ_hAY_QWjtyKVlD3HZhjpi32AbfOOtCTnX2OQtnGKDu7Ybgkm-bXKlhYlQ5zImbKKPx2jfmRDh0-6coIfLb_fz6-nt3dX3-fnt1PI8zLSuHJvVikKpKs5krezCkFKBU0wxYRxYKpwRblGRynLHmLNSOicZBVoBd-UEnWzr5pl-DhCTXvtoIQTTQDtELYkUcjYTGVRb0ObhYw9Od71fm36jKdGjb73So0o9atWjb_3Ht37JqZ93PYbFGup_iTvBGfiyA0zMjlxvGuvjO8dIKcsy7xN0tuWefYDNf39AX9w8jFH5BspSoKg</recordid><startdate>200806</startdate><enddate>200806</enddate><creator>Connolly, David</creator><creator>Black, Amanda</creator><creator>Murray, Liam J.</creator><creator>Nambirajan, Thiagarajan</creator><creator>Keane, Patrick F.</creator><creator>Gavin, Anna</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200806</creationdate><title>The utility of prostate‐specific antigen velocity thresholds in clinical practice: a population‐based analysis</title><author>Connolly, David ; Black, Amanda ; Murray, Liam J. ; Nambirajan, Thiagarajan ; Keane, Patrick F. ; Gavin, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4470-d9f25d81e389427d8cba038ef82826afec16fa6fb909c4f22fc77ff721e19e4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>cancer</topic><topic>Cohort Studies</topic><topic>diagnosis</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>initial PSA</topic><topic>Ireland</topic><topic>Male</topic><topic>Male genital diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>population</topic><topic>prostate</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Registries</topic><topic>Reproducibility of Results</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Statistics, Nonparametric</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><topic>velocity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Connolly, David</creatorcontrib><creatorcontrib>Black, Amanda</creatorcontrib><creatorcontrib>Murray, Liam J.</creatorcontrib><creatorcontrib>Nambirajan, Thiagarajan</creatorcontrib><creatorcontrib>Keane, Patrick F.</creatorcontrib><creatorcontrib>Gavin, Anna</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Connolly, David</au><au>Black, Amanda</au><au>Murray, Liam J.</au><au>Nambirajan, Thiagarajan</au><au>Keane, Patrick F.</au><au>Gavin, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The utility of prostate‐specific antigen velocity thresholds in clinical practice: a population‐based analysis</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2008-06</date><risdate>2008</risdate><volume>101</volume><issue>12</issue><spage>1507</spage><epage>1512</epage><pages>1507-1512</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>OBJECTIVE
To investigate the ability of prostate‐specific antigen velocity (PSAV) to predict prostate cancer, and assess the test characteristics of several PSAV thresholds for identifying prostate cancer and high‐grade cancers.
PATIENTS AND METHODS
From a population‐based database of PSA results, men with an initial PSA level of <10.0 ng/mL, taken between I January 1994 and 31 December 2003, were identified. Those with three or more PSA tests before diagnosis, taken over ≥18 months, were included. Men were followed for a diagnosis of prostate cancer or histologically confirmed benign disease until 31 December 2003.
RESULTS
In all, 24 709 men were included, with 716 (2.9%) diagnosed with prostate cancer and 1488 (6.0%) with benign histology. The mean (10.38 vs 0.43 ng/mL/year) and median (1.47 vs 0.03 ng/mL/year) PSAV were considerably higher in men with prostate cancer than in those with no cancer (P < 0.001). There was no PSAV threshold that could reliably identify prostate cancer or high‐grade cancers without requiring many men to proceed to prostate biopsy.
CONCLUSION
In this population, PSAV had additional value over one PSA value in identifying men with prostate cancer. Many men with prostate cancer might have a ‘normal’ (<0.75 ng/mL/year) PSAV. As with total PSA level, there was no PSAV threshold that could reliably predict prostate cancer, but rather a continuum of risk of cancer associated with PSAV level.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18341627</pmid><doi>10.1111/j.1464-410X.2008.07470.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2008-06, Vol.101 (12), p.1507-1512 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70767556 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Biological and medical sciences cancer Cohort Studies diagnosis Gynecology. Andrology. Obstetrics Humans initial PSA Ireland Male Male genital diseases Medical sciences Middle Aged Nephrology. Urinary tract diseases population prostate Prostate-Specific Antigen - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - pathology Registries Reproducibility of Results Risk Factors Sensitivity and Specificity Statistics, Nonparametric Tumors Tumors of the urinary system Urinary tract. Prostate gland velocity |
| title | The utility of prostate‐specific antigen velocity thresholds in clinical practice: a population‐based analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A59%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20utility%20of%20prostate%E2%80%90specific%20antigen%20velocity%20thresholds%20in%20clinical%20practice:%20a%20population%E2%80%90based%20analysis&rft.jtitle=BJU%20international&rft.au=Connolly,%20David&rft.date=2008-06&rft.volume=101&rft.issue=12&rft.spage=1507&rft.epage=1512&rft.pages=1507-1512&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/j.1464-410X.2008.07470.x&rft_dat=%3Cproquest_cross%3E70767556%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70767556&rft_id=info:pmid/18341627&rfr_iscdi=true |